Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.

Klampatsa A, O'Brien SM, Thompson JC, Rao AS, Stadanlick JE, Martinez MC, Liousia M, Cantu E, Cengel K, Moon EK, Singhal S, Eruslanov EB, Albelda SM.

Oncoimmunology. 2019 Jul 13;8(9):e1638211. doi: 10.1080/2162402X.2019.1638211. eCollection 2019.

PMID:
31428531
2.

Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-β and chronic bleomycin-induced fibrosis.

Kimura T, Monslow J, Klampatsa A, Leibowitz M, Sun J, Liousia M, Woodruff P, Moon E, Todd L, Puré E, Albelda SM.

Am J Physiol Lung Cell Mol Physiol. 2019 Aug 1;317(2):L271-L282. doi: 10.1152/ajplung.00071.2019. Epub 2019 Jun 12.

PMID:
31188013
3.

Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.

O'Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang WT, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, Singhal S, Eruslanov EB, Moon EK, Albelda SM.

Cancer Immunol Res. 2019 Jun;7(6):896-909. doi: 10.1158/2326-6066.CIR-18-0713. Epub 2019 May 3.

PMID:
31053597
4.

Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy.

Davis RW 4th, Snyder E, Miller J, Carter S, Houser C, Klampatsa A, Albelda SM, Cengel KA, Busch TM.

Photochem Photobiol. 2019 Jan;95(1):430-438. doi: 10.1111/php.13040. Epub 2018 Nov 26.

PMID:
30357853
5.

A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.

Davis RW 4th, Papasavvas E, Klampatsa A, Putt M, Montaner LJ, Culligan MJ, McNulty S, Friedberg JS, Simone CB 2nd, Singhal S, Albelda SM, Cengel KA, Busch TM.

Lasers Surg Med. 2018 Jul;50(5):440-450. doi: 10.1002/lsm.22934. Epub 2018 May 25.

6.

Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.

Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Sallé F, Hiroshima K, Kadota K, Klampatsa A, Stang NL, Lindenmann J, Litzky LA, Marchevsky A, Medeiros F, Montero MA, Moore DA, Nabeshima K, Pavlisko EN, Roggli VL, Sauter JL, Sharma A, Sheaff M, Travis WD, Vigneswaran WT, Vrugt B, Walts AE, Tjota MY, Krausz T, Husain AN.

Mod Pathol. 2018 Apr;31(4):598-606. doi: 10.1038/modpathol.2017.170. Epub 2018 Jan 12.

7.

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, Parente-Pereira AC, Whilding LM, van der Stegen SJ, Woodman N, Sheaff M, Cochran JR, Spicer JF, Maher J.

Oncoimmunology. 2017 Aug 14;6(12):e1363137. doi: 10.1080/2162402X.2017.1363137. eCollection 2017.

8.

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).

Klampatsa A, Haas AR, Moon EK, Albelda SM.

Cancers (Basel). 2017 Sep 1;9(9). pii: E115. doi: 10.3390/cancers9090115. Review.

9.

Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.

Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J.

Cancer Lett. 2017 May 1;393:52-59. doi: 10.1016/j.canlet.2017.02.015. Epub 2017 Feb 20.

PMID:
28223167

Supplemental Content

Loading ...
Support Center